References
- Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436–42
- Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997;349:1498–504
- Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression. JAMA 1998;280:1665–72
- Anderson IM, Nutt DJ, Deakin JFW. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 2000;14: 3–20
- Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8–19
- Geddes JR, Butler R, Hatcher S. Depressive disorders. Clinical Evidence Concise 2002;8:188–191
- NIMH/NIH Consensus Development Conference Statement. Mood disorders. Am J Psychiatry 1985;142: 469–76
- Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653–61
- Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093–9
- Thase ME, Sullivan LR. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs 1995;4:261–77
- DIN-LINK Data, Antidepressant Data, Report 19
- Judd LL, Ahiskal HS, Maser JD, et al. A prospective 12 year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1988;55:694–700